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Abstract: Serum high-sensitivity C-reactive protein (hsCRP) and serum uric acid (SUA) are biomarkers
that predict chronic inflammation and cardiovascular dysfunction. Therefore, we aimed to investigate
the association between sleep duration, hsCRP, and SUA in Korean women. Cross-sectional data
from the Seventh Korea National Health and Nutrition Examination Survey was analyzed. The odds
ratio (OR) and 95% confidence intervals (CIs) for an association between higher hsCRP (>2.0 mg/L)
or higher SUA (>5.6 mg/dL) and sleep duration were calculated using multiple logistic regression
analyses after adjusting for potential confounders. In total, 6151 women were included in the analysis.
There was a U-shaped relationship between continuous sleep duration, hsCRP, and SUA. Compared
to those who slept for 7–8 h, the ORs (95% CIs) for higher hsCRP were 1.43 (0.95–2.16) in short sleepers
and 1.64 (1.09–2.48) in long sleepers after adjusting for confounders. Compared with those who slept
for 7–8 h, the ORs (95% CIs) for higher SUA were 1.54 (1.04–2.26) in short sleepers and 1.94 (1.27–2.96)
in long sleepers after adjusting for confounders. We found a U-shaped association between sleep
duration, hsCRP, and SUA in Korean women. 7–8 h sleep was associated with lower level of hsCRP
and SUA in Korean women.
Keywords: sleep duration; high-sensitivity C-reactive protein; uric acid; inflammation
1. Introduction
Sleep plays a vital role in human health and well-being [1,2]. Various sleep related components,
such as alertness, timing of sleep, sleep efficiency, and sleep duration, are involved in systemic processes
and systems, such as metabolism and the cardiovascular system [1]. Sleep duration is one of the most
important components of sleep and it is easily quantifiable. Many studies have shown that too little
and too much sleep are associated with diabetes, cerebrovascular diseases, cardiovascular diseases, and
all-cause mortality [3–5]. One potential pathway linking sleep duration and cardiometabolic health is
systemic inflammation.
C-reactive protein (CRP) is a stable inflammation marker and predictor of cardiovascular
diseases [6]. CRP is secreted by the liver in response to various inflammatory cytokines, such
as interleukin-6 (IL-6) [7]. Recently, a high-sensitivity C-reactive protein (hsCRP) test that can detect
CRP more accurately and at lower concentrations has been developed and widely used due to its
high predictive value [8]. Previous studies have established that elevated hsCRP is associated with
cardiovascular diseases, diabetes, and mortality [9,10].
Serum uric acid (SUA) is the final product of both intracellular and extracellular purine metabolism,
and requires xanthine-oxidoreductase enzyme activity [11]. SUA has both pro-oxidant and anti-oxidant
activity. Accumulation of reactive oxygen species with SUA production can lead to predominantly
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pro-oxidant and pro-inflammatory effects [11–13]. SUA also induces the expression of hepatic
inflammatory molecules by activating the nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-kB) signaling cascade [13]. Many epidemiologic studies have noted that higher SUA is significantly
associated with the risk of hypertension [14,15], heart failure [16], and mortality due to cardiovascular
events [17]. Further, several studies have reported that higher SUA is strongly associated with coronary
atherosclerosis, left ventricular hypertrophy, and mortality due to cardiovascular events especially in
women [17–19].
Although previous studies have investigated the association between sleep duration, hsCRP,
and SUA, the results were inconsistent [20–24]. Some studies found that short sleep duration was
associated with elevated CRP [20,21]. Richardson et al. [22] showed that short sleep duration was
significantly associated with elevated CRP only in men not in women. Grandner et al. [23] found that
both short and long sleep duration were associated with elevated CRP; however, these associations
varied according to sex and race/ethnicity. A recent study reported that sleep duration was inversely
associated with SUA in an elderly Mediterranean population with metabolic syndrome or obesity [24].
Considering the importance of sleep duration and its impact on chronic inflammation, large
population-based studies are needed to investigate the association between sleep duration, hsCRP, and
SUA. Therefore, we aimed to investigate the association between sleep duration, hsCRP, and SUA in
Korean women.
2. Materials and Methods
2.1. Study Design and Population
We used data from the 2016–2017 Korean National Health and Nutrition Examination Survey
(KNHANES) VII performed by the Korea Centers for Disease Control and Prevention (KCDC). Detailed
information about KNHANES is described on the website (https://knhanes.cdc.go.kr) and previous
study [25].
There were 7143 female participants older than 20 years in KNHANES VII. We excluded 641
participants who had missing data regarding sleep duration, 693 participants with missing data
regarding hsCRP, and 612 participants with missing data regardingSUA. Finally, the data from 6151
women were included the analysis (Figure 1). Informed consent was obtained from all participants
during the survey by KCDC. The Institutional Review Board of Yongin Severance Hospital approved
this study (IRB No 9-2019-0008).
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2.2. Covariates
Body mass index (BMI) was calculated as body weight (kg) divided by the square of height
(m). Blood pressure was measured using a Baumanometer Wall Unit 33(0850) in the sitting position
after 5 min of rest. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were recorded
three times and the mean value of last two measurements was recorded. Fasting glucose and total
cholesterol (TC) levels were measured after an overnight fast using a Hitachi 7600-210 Chemistry
Analyzer (Hitachi Co., Tokyo, Japan).
Smoking history was defined as current smokers or those who had smoked over 100 cigarettes
during their lifetime. An alcohol drinker was defined as an individual who consumed alcohol more
than 2 or 3 times a week. Exercise of moderate intensity for more than 150 min a week or high intensity
for more than 75 min a week was defined as regular exercise. Diabetes mellitus was defined as a blood
glucose level of more than 126 mg/dL, taking diabetic medication, or undergoing insulin treatment,
or a diagnosis of diabetes mellitus by a physician. Hypertension was defined as SBP ≥ 140 mmHg
or DBP ≥ 90 mmHg or taking antihypertensive medication. Hypercholesterolemia was defined as
total cholesterol ≥ 240 mg/dL or taking cholesterol lowering medication. Cardiovascular disease was
defined as a diagnosis of stroke, myocardial infarction, or angina pectoris by a physician. EuroQol-5D
(EQ5D) is a well-validated instrument to evaluate the quality of life. EQ5D consists of 5 dimensions:
mobility, daily activity, pain or discomfort, self-care, and anxiety or depression [26]. We assessed
depressive symptoms using a patient health questionnaire (PHQ)-9 that consisted of nine questions for
screening depression in primary care; the cut-off value to identify depressive symptoms was 10 [27].
2.3. Assessment of High-Sensitivity CRP and Uric Acid Levels
The serum level of hsCRP was measured by an immunoturbidimetry method using Cobas (Roche,
Germany). In the workshop by Centers for Disease Control and American Heart Association in 2002,
the cut-points of hsCRP concentrations for purposes of cardiovascular risk assessment were classified
as follows; low risk (<1.0 mg/L), average risk (1.0 to 3.0 mg/L), and high risk (>3.0 mg/L) [6]. In the
Jupiter trial, participants who were indicated by hsCRP levels >2 mg/L categorized to high vascular
risk [28]. High hsCRP was defined as hsCRP levels > 2.0 mg/L based on the previous studies [6,28]. In
an epidemiological follow-up data from National Health and Nutrition Examination Survey, deaths
due to ischemic heart disease in women significantly increased when SUA levels were in the highest
quartile (5.6 mg/dL) compared with the lowest quartile (4.0 mg/dL) [17]. The Princeton school district
family study defined the participants who had hyperuricemia when they had above a 90th percentile
of SUA level [29]. The level of SUA was measured by Uricase, a colorimetry method using a Hitachi
7600-210 automatic biochemical analyzer (Hitachi, Japan). High SUA level was defined as SUA levels
exceeding the upper 90th percentile (=5.6 mg/dL) based on the previous studies [17,29].
2.4. Assessment of Sleep Duration
Participants were asked the following question “When do you go to bed and wake up on a
weekday?” and “When do you go to bed and wake up on a weekend?” Sleep duration was calculated
as follows: (sleep duration on a weekday × 5 + sleep duration on a weekend × 2)/7. The total time
spent sleeping was recorded as a continuous variable (e.g., 7 h 31 min). Moreover, we classified the
sleep duration into five groups as follows: <6 h, 6–7 h, 7–8 h, 8–9 h, ≥9 h.
2.5. Statistical Analyses
Due to the nature of the KNHANES sampling design, we analyzed the data after considering
a complex sample design. Data were presented as mean ± standard errors (SEs) for continuous
variables or percentage (SEs) for categorical variables. Sleep duration was categorized as follows:
<6, 6–7, 7–8, 8–9, and ≥9 h. Clinical characteristics of participants were compared using a weighted
analysis of variance for continuous variables or a weighted chi-square test for categorical variables. To
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determine the relationship between continuous sleep duration, serum hsCRP, and SUA, we developed
a restricted cubic spline curve analysis, which was applied in an unadjusted model using the R package,
version 3.4.4 (http://www.R-project.org). The detailed information about ‘R’ code are described in
the Appendix A. To build a model, independent variables were examined in the univariate model
(Appendix B). Then, variables that were closely associated with the serum hsCRP or SUA (p < 0.05)
were imported into the final multivariate models, along with variables that indicate to be risk factors of
higher hsCRP or SUA in previous studies [30,31]. Before analysis, we checked the multicollinearity
between the explanatory (predictor) variables. All variance inflation factors (VIFs) were below 5.
The odds ratio (OR) and 95% confidence intervals (95% CIs) were calculated using multiple logistic
regression. In model 2, we adjusted for age and BMI. In model 3, we adjusted for age, BMI, smoking,
alcohol intake, exercise, hypertension, diabetes mellitus, hypercholesterolemia, and cardiovascular
disease. In model 4, we additionally adjusted for EQ5D and patient health questionnaire-9 (PHQ-9)
results. All statistical analyses were performed using SPSS version 25.0 (SPSS version 25.0; IBM Corp.,
Armonk, NY, USA). All statistical tests were two-sided and the results were considered significant at
p < 0.05.
3. Results
The general characteristics of the study population according to sleep duration are described
in Table 1. A large proportion of women (31.5%) reported sleeping for 7–8 h. Participants who
typically slept for less than 6 h were significantly older than the other sleep duration groups (p < 0.001).
Short sleepers (<6 h) had significantly higher BMI, SBP, DBP, and fasting glucose, HbA1c, and total
cholesterol levels. The prevalence of hypertension, diabetes mellitus, and hypercholesterolemia was
significantly higher among short duration sleepers. The prevalence of cardiovascular disease was
higher among long sleepers (≥9 h), although this was not statistically significant (p = 0.594). With
respect to health-related behavior, long sleepers smoked more (p = 0.002) and exercised less (p = 0.001),
whereas short sleepers consumed more alcohol (p = 0.047). Regarding quality of life, the EQ5D scores
were significantly lower among short sleepers (0.93 ± 0.01) and long sleepers (0.93 ± 0.01) (p < 0.001).
Regarding mental health, the PHQ-9 scores were significantly higher among short sleepers (4.0 ± 0.3)
and long sleepers (3.7 ± 0.3) (p < 0.001).
Table 1. General characteristics of the study population according to sleep duration.*
Sleep Duration
< 6 h 6–7 h 7–8 h 8–9 h ≥ 9 h p-Value
N 840 1471 1939 1289 612
Age 52.7 ± 0.8 48.9 ± 0.6 47.1 ± 0.5 46.4 ± 0.6 48.7 ± 1.1 <0.001
BMI (kg/m2) 24.3 ± 0.2 23.4 ± 0.1 23.3 ± 0.1 23.1 ± 0.1 23.3 ± 0.2 <0.001
SBP (mmHg) 118.0 ± 0.6 115.9 ± 0.6 114.4 ± 0.5 113.8 ± 0.8 114.6 ± 0.7 <0.001
DBP (mmHg) 74.5 ± 0.4 74.3 ± 0.2 73.1 ± 0.3 72.7 ± 0.3 72.1 ± 0.4 <0.001
Glucose (mg/dL) 101.9 ± 1.2 97.7 ± 0.6 96.4 ± 0.6 97.0 ± 0.7 98.4 ± 0.9 <0.001
HbA1c (%) 5.8 ± 0.0 5.6 ± 0.0 5.6 ± 0.0 5.6 ± 0.0 5.6 ± 0.0 <0.001
Total cholesterol (mg/dL) 198.5 ± 1.7 196.2 ± 1.1 193.2 ± 1.1 192.8 ± 1.0 196.0 ± 1.8 0.030
hsCRP (mg/L) 1.23 ± 0.08 1.02 ± 0.05 1.02 ± 0.05 1.06 ± 0.04 1.26 ± 0.09 0.057
SUA (mg/dL) 4.53 ± 0.04 4.35 ± 0.03 4.35 ± 0.02 4.33 ± 0.04 4.42 ± 0.05 0.002
Hypertension (yes) † 32.2 (2.3) 22.9 (1.3) 21.6 (1.3) 21.0 (1.4) 25.9 (2.3) <0.001
Diabetes (yes) † 13.9 (1.5) 9.3 (0.9) 8.0 (0.9) 9.5 (0.8) 9.8 (1.3) 0.001
Cardiovascular diseases (yes) † 2.8 (0.6) 2.8 (0.4) 3.0 (0.4) 3.2 (0.6) 4.1 (0.9) 0.594
Hypercholesterolemia (yes) † 27.1 (1.7) 24.1 (1.2) 20.6 (1.0) 19.9 (1.3) 19.8 (1.8) 0.001
Smoking (yes) † 13.0 (1.1) 9.8 (1.1) 9.4 (0.7) 8.4 (0.8) 14.1 (1.6) 0.002
Alcohol (yes) † 14.2 (1.2) 10.2 (0.8) 13.2 (0.7) 12.3 (1.0) 13.4 (1.5) 0.047
Physical activity (yes) † 44.0 (1.8) 46.3 (1.6) 45.6 (1.6) 44.1 (1.6) 33.7 (2.4) 0.001
EQ5D 0.93 ± 0.01 0.95 ± 0.00 0.95 ± 0.00 0.95 ± 0.00 0.93 ± 0.01 <0.001
PHQ-9 4.0 ± 0.3 2.8 ± 0.2 3.1 ± 0.1 3.0 ± 0.2 3.7 ± 0.3 <0.001
Abbreviations: BMI, body-mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated
hemoglobin; hsCRP, high-sensitivity C-reactive protein; SUA, serum uric acid; EQ5D, EuroQol-5D; PHQ-9, patient
health questionnaire-9. † Categorical variables. * Data are presented as mean± standard errors (SEs) for continues
variables or percentage (SE) for categorical variables.
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Figure 2A,B show the U-shaped relationship of sleep duration with hsCRP and SUA levels,
respectively. Figure 2C,D show the proportion of individuals with higher hsCRP (>2.0 mg/L) and
SUA (>5.6 mg/dL) levels, respectively. The proportion of individuals with high hsCRP level was
significantly different according to sleep duration (15.0% for <6 h, 11.6% for 6–7 h, 10.7% for 7–8 h,
13.1% for 8–9 h, and 14.4% for >9 h; p < 0.001). The proportion of individuals with higher SUA levels
was significantly different according to sleep duration (15.1% for <6 h, 10.3% for 6–7 h, 7.9% for 7–8 h,
10.8% for 8–9 h, and 13.0% for >9 h; p < 0.001). U-shaped curves with the nadir in the appropriate
sleep duration range (7–8 h) were seen for both hsCRP and SUA levels.
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Figure 2. Association between serum high-sensitivity C-reactive protein (CRP), serum uric acid (SUA),
and sleep duration in Korean women. (A) The relationship between continuous values of hsCRP and
sleep duration. (B) The relationship between continuous values of SUA and sleep duration. (C) The
proportion of patients with higher serum hsCRP level according to sleep duration categories. (D) The
proportion of patients with higher SUA level according to sleep duration categories. Solid blue line
(restricted cubic spline regression line) indicate predicted hsCRP and SUA by sleep duration and
shaded area indicate the 95% confidence intervals.
Table 2 shows the ORs and 95% CIs for higher hsCRP levels (>2.0 mg/L) according to sleep
duration. Compared with those who typically slept for 7–8 h, the ORs (95% CIs) for higher hsCRP
levels were 1.48 (1.11–1.97) in short sleepers and 1.41 (1.04–1.90) in long sleepers in an unadjusted
model (model 1). The ORs (95% CIs) for higher hsCRP levels were 1.43 (0.95–2.16) in short sleepers
and 1.64 (1.09–2.48) in long sleepers after adjusting for age, B I, hypertension, diabetes mellitus,
hypercholesterolemia, cardiovascular disease, physical activity, s oking, alcohol consumption, and
EQ5D and PHQ-9 results (model 4).
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Table 2. Odds ratio and 95% confidence intervals for higher high-sensitivity C-reactive protein
(>2.0 mg/L) according to sleep duration.
Sleep Duration
< 6 h 6–7 h 7–8 h 8–9 h ≥ 9 h
Model 1 1.48 (1.11–1.97) 1.10 (0.88–1.38) Ref (1) 1.26 (0.99–1.59) 1.41 (1.04–1.90)
Model 2 1.20 (0.89–1.62) 1.09 (0.86–1.39) Ref (1) 1.32 (1.06–1.65) 1.48 (1.10–1.99)
Model 3 1.28 (0.93–1.77) 1.14 (0.87–1.45) Ref (1) 1.37 (1.10–1.72) 1.42 (1.04–1.93)
Model 4 1.43 (0.95–2.16) 1.19 (0.87–1.64) Ref (1) 1.21 (0.87–1.70) 1.64 (1.09–2.48)
Model 1: unadjusted; Model 2: adjusted for age and BMI; Model 3: adjusted for age, BMI, hypertension, diabetes
mellitus, hypercholesterolemia, cardiovascular diseases, physical activity, smoking, and alcohol consumption;
Model 4: adjusted for age, BMI, hypertension, diabetes mellitus, hypercholesterolemia, cardiovascular diseases
physical activity, smoking, alcohol consumption, and EQ5D and PHQ-9 scores.
Table 3 shows the ORs and 95% CIs for higher SUA levels (>5.6 mg/dL) according to sleep duration.
Compared with those who typically slept for 7–8 h, the ORs (95% CIs) for higher SUA level were 2.07
(1.53–2.81) in short sleepers and 1.74 (1.27–2.39) in long sleepers in an unadjusted model (model 1).
The ORs (95% CIs) for higher SUA level were 1.54 (1.04–2.26) in short sleepers and 1.94 (1.27–2.96)
in long sleepers after adjusting for age, BMI, hypertension, diabetes mellitus, hypercholesterolemia,
cardiovascular diseases, physical activity, smoking, alcohol consumption, and EQ5D and PHQ-9 results
(model 4).
Table 3. Odds ratio and 95% confidence intervals for higher serum uric acid (>5.6 mg/dL) according to
sleep duration.
Sleep Duration
< 6 h 6–7 h 7–8 h 8–9 h ≥ 9 h
Model 1 2.07 (1.53–2.81) 1.35 (1.02–1.78) Ref (1) 1.42 (0.98–2.06) 1.74 (1.27–2.39)
Model 2 1.74 (1.30–2.33) 1.33 (1.01–1.75) Ref (1) 1.49 (1.02–2.17) 1.78 (1.29–2.46)
Model 3 1.81 (1.37–2.37) 1.40 (1.05–1.86) Ref (1) 1.60 (1.10–2.35) 1.82 (1.34–2.49)
Model 4 1.54 (1.04–2.26) 1.13 (0.79–1.62) Ref (1) 1.35 (0.95–1.94) 1.94 (1.27–2.96)
Model 1: unadjusted; Model 2: adjusted for age and BMI; Model 3: adjusted for age, BMI, hypertension, diabetes
mellitus, hypercholesterolemia, cardiovascular diseases, physical activity, smoking, and alcohol consumption;
Model 4: adjusted for age, BMI, hypertension, diabetes mellitus, hypercholesterolemia, cardiovascular diseases,
physical activity, smoking, alcohol consumption, and EQ5D and PHQ-9 scores.
4. Discussion
Our study identified significant U-shaped associations between sleep duration, hsCRP, and SUA.
We demonstrated that in a cohort of Korean women, individuals who sleep for <6 h or ≥9 h per day
were significantly more likely to have higher levels of hsCRP and SUA compared to those who sleep for
an average of 7–8 h per day. Regarding SUA, this association was still significant after adjusting for age,
BMI, underlying diseases (hypertension, diabetes mellitus, hypercholesterolemia, and cardiovascular
diseases), health related behavior (physical activity, smoking, and alcohol consumption), quality of life
as measured by the EQ5D, and depressive symptoms as measured by the PHQ-9. After adjusting for
the same confounding factors, the significant association between sleep duration and higher hsCRP
was attenuated in short sleepers who slept for less than 6 h although not statistically significant.
To date, there have been inconsistent results about the relationship between sleep duration and
serum hsCRP. Several previous studies have shown that a shorter sleep duration was associated
with higher levels of CRP [20,21]. The longitudinal Whitehall II study [21] on London-based office
employees aged 35–55 years showed that shorter sleep duration (≤ 5 h) and decreased sleep duration
was significantly associated with higher levels of CRP. However, this association was diminished
after adjusting for cardiometabolic risk factors such as BMI, blood pressure, cholesterol, and diabetes.
A Taiwanese study [20] found that short sleepers (≤ 5.5 h) had higher levels of CRP when compared
with long sleepers (>8 h). Consistent with our study, NHANES in US indicated that short and
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long sleep duration were associated with elevated CRP levels; however, the significant relationship
between short sleep duration (<5 h) and elevated CRP levels disappeared after adjusting for medical
comorbidities [23]. A meta-analysis of population-based studies showed that long sleep duration
was associated with higher CRP levels, but short sleep duration was not [32]. Our results confirm
these results.
Regarding SUA, few studies have investigated the relationship between sleep duration and
SUA. With recent studies identifying that SUA is an important risk factor for cardiovascular diseases,
more studies are needed to determine factors that affect the SUA level. Wiener et al. [33] suggested
possible associations between sleep variables (daytime sleepiness, snoring, and additive composite
score) and high SUA; however, they found no significant association between sleep duration and high
SUA. In a recent study conducted as part of a PREDIMED-Plus trial, Papandreou et al. [24] found an
inverse association between sleep duration and SUA. However, this study was limited to only elderly
participants with metabolic risk factors.
The reasons for the discrepancies in these studies might be due to different categories of sleep
duration, heterogeneity of study groups, and confounding variables. Our study enrolled Korean
women aged over 20 years. We not only investigated the relationship between categorized sleep
duration, serum hsCRP, and SUA but also the continuous relationship between sleep duration, serum
hsCRP, and SUA. We also adjusted statistical models for possible confounders including metabolic
risk factors, quality of life, and depressive symptoms. Our study confirmed the association between
extreme (short or long) sleep duration and two markers of systemic inflammation, hsCRP, and SUA.
The mechanisms underlying the associations between sleep duration, hsCRP, and SUA are still
uncertain. Short and long sleep duration may share some mechanisms involving elevated hsCRP and
SUA levels.
One possible shared mechanism may involve the function of the sympathetic nerve system related
to sleep deprivation or disordered sleep that leads to elevated catecholamine levels [34]. Dysregulated
autonomic function can lead to changes in inflammatory gene expression due to adrenergic signaling
and the subsequent production of inflammatory markers such as NF-kB or hsCRP [35]. A possible role
of catecholamines in the pathogenesis of hyperuricemia has also been studied in animal models [36,37].
Several potential mechanisms may contribute to the relationship between short sleep duration and
elevated hsCRP and SUA. Loss of sleep is associated with multiple hormonal changes such as reduced
leptin and melatonin as well as increased cortisol and ghrelin levels [38]. These hormonal changes can
lead to impaired glucose metabolism, hyperinsulinemia, obesity, hypertension, and dyslipidemia [38].
In this study, we found that short sleepers had a higher BMI, SBP, and DBP, and levels of blood glucose,
HbA1c, and cholesterol. As described in many previous studies, these metabolic risk parameters are
closely associated with elevated levels of hsCRP and SUA [9,10,15–17].
The potential mechanisms underlying the association between long sleep duration and elevated
hsCRP and SUA are more speculative. First, a long sleep duration could be the result an undiagnosed
illness or comorbidities that cause fatigue and lethargy [39]. Chronic inflammation is known to be
involved in the main pathophysiology of many chronic diseases [40]. Although we adjusted for possible
chronic diseases such as hypertension, dyslipidemia, diabetes, and cardiovascular diseases, there might
be other chronic diseases, such as sleep apnea and malignancy, which were not accounted for. Second,
sleeping for a prolonged period is associated with depression and an unhealthy lifestyle such as less
physical activity [3]. Our study also found that both short and long sleepers have more depressive
symptoms. Regarding health-related behaviors, long sleepers exercised less and smoked more. Several
studies have shown that depression and inflammation are related [41,42]. The relationships between
less physical activity and smoking or chronic inflammation are well established [43,44].
Our study has some limitations that need to be considered. First, owing to the cross-sectional
study design, a cause-and-effect relationship could not be determined. Second, since we included
only Korean women, generalization of our results to other sexes, races, and ethnicities should be done
with caution. Third, we measured sleep duration using a self-reported questionnaire. The objective
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measurement of actual sleep duration and the consideration of other sleep variables, such as sleep
quality, are needed to clarify the relationship between sleep health and inflammatory markers. Finally,
there may be other residual factors that we did not adequately take into account. Despite these
limitations, this study is the first large population-based study to investigate the association between
sleep duration and serum hsCRP and SUA levels in Korean women.
5. Conclusions
Altogether, we found a U-shaped association between sleep duration, hsCRP, and SUA in Korean
women. Our results indicate that 7–8 h sleep was associated with lower level of hsCRP and SUA in
Korean women.
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Appendix A
Restricted cubic spline curve analyses: R package, version 3.4.4 (http://www.R-project.org).
Code
install.packages(“rms”)
library(rms)
rawdata=read.csv(“D:/R/sleepduration.csv”)
dim(rawdata) attach(rawdata) names(rawdata)
HE_hsCRP_1<-rawdata$HE_hsCRP_
HE_Uacid<-rawdata$HE_Uacid
sleep duration<-rawdata$ts60
f_uni <- ols(HE_hsCRP_1~ rcs(sleep duration)
data=rawdata, x=TRUE)
sleep duration <- seq(0,12,2)
p_uni <- Predict(f_uni, sleep duration = sleep duration)
plot(p_uni,xlab=‘ sleep duration ‘, ylab=‘HS CRP’)
f_uni <- ols(HE_Uacid~ rcs(ts sleep duration),data=rawdata, x=TRUE)
sleep duration <- seq(0,12,2)
p_uni <- Predict(f_uni, sleep duration = sleep duration) plot(p_uni,xlab=‘ sleep duration’, ylab=‘Uacid’)
Appendix B
Table A1. Univariate analysis: Factors associated with hsCRP and SUA.
hsCRP Serum Uric Acid
Exp (B) 95% CI p-Value Exp (B) 95% CI p-Value
Age 1.009 1.003–1.015 0.006 1.015 1.007–1.022 <0.001
BMI (kg/m2) 1.210 1.182–1.238 <0.001 1.157 1.132–1.183 <0.001
Hypertension (yes) 0.569 0.477–0.679 <0.001 0.444 0.359–0.548 <0.001
Diabetes mellitus (yes) 0.452 0.351–0.582 <0.001 0.456 0.337–0.616 <0.001
Hypercholesterolemia (yes) 0.751 0.627–0.900 0.002 0.628 0.504–0.782 <0.001
Cardiovascular disease (yes) 0.680 0.482–0.679 0.028 0.529 0.389–0.719 <0.001
Physical activity (yes) 1.281 1.053–1.557 0.013 1.019 0.847–1.226 0.840
Smoking (yes) 0.712 0.552–0.919 0.009 0.556 0.419–0.739 <0.001
Alcohol (yes) 1.122 0.814–1.546 0.482 0.708 0.546–0.916 0.009
EQ5D 0.223 0.124–0.400 <0.001 0.213 0.109–0.416 <0.001
PHQ-9 1.018 0.988–1.048 0.238 1.034 1.001–1.069 0.045
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